Olmesartan Medoxomilo + Hidroclorotiazida Pentafarma (Olmesartan Medoxomil, Hydrochlorothiazide)

Olmesartan medoxil, the active ingredient in Olmesartan Medoxomilo + Hidroclorotiazida Pentafarma, is an angiotensin II receptor blocker presented as a tablet for oral use. It treats hypertension, often in combination with a diuretic, and is used in adult patients. GNH USA supplies Olmesartan Medoxomilo + Hidroclorotiazida Pentafarma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

GNH USA supplies Olmesartan Medoxomilo + Hidroclorotiazida Pentafarma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

Olmesartan medoxil combined with hydrochlorothiazide is indicated for management of high blood pressure within the renin‑angiotensin‑aldosterone system pathway.

- Hypertension: lowers systolic and diastolic blood pressure to reduce cardiovascular risk. - Hypertension with fluid retention: provides additional diuretic effect to improve blood pressure control. - Resistant hypertension: used as part of a multi‑drug regimen when blood pressure remains uncontrolled. - Hypertension in patients with metabolic syndrome: helps achieve target pressures while minimizing impact on glucose metabolism. - Hypertension in elderly patients: offers effective blood pressure reduction with a once‑daily dosing schedule. - Hypertension in patients with chronic kidney disease: assists in blood pressure control while addressing volume overload.

Adverse reactions may range from mild to severe and should be monitored during therapy.

Common Side Effects: - Dizziness: transient light‑headedness, especially after the first dose. - Headache: mild to moderate intensity. - Fatigue: general feeling of tiredness. - Increased urination: due to the diuretic component. - Electrolyte imbalance: mild changes in potassium or sodium levels. - Mild gastrointestinal discomfort: occasional nausea or abdominal pain.

Serious or Rare Side Effects: - Angioedema: swelling of face, lips, tongue, or throat requiring urgent care. - Severe electrolyte disturbances: significant hyper‑ or hypokalemia. - Acute kidney injury: sudden decline in renal function. - Hepatic dysfunction: elevated liver enzymes. - Severe hypotension: marked drop in blood pressure leading to syncope. - Allergic rash or Stevens‑Johnson syndrome: extensive skin reactions.

Before initiating therapy, clinicians should evaluate patient history and monitor relevant parameters.

- Renal function: assess baseline creatinine and eGFR, adjust if impaired. - Electrolytes: check serum potassium and sodium before and during treatment. - Pregnancy: avoid use; teratogenic risk associated with ARBs. - Concomitant drugs: review for potential additive potassium‑sparing effects. - Elderly patients: start at lower dose and monitor for orthostatic hypotension. - Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Olmesartan medoxil + hydrochlorothiazide may interact with several drug classes; monitoring is essential.

Major Interactions (Avoid): - Potassium‑sparing diuretics or supplements: risk of hyperkalaemia. - Aliskiren (in diabetic patients): increased renal adverse events. - NSAIDs: may blunt antihypertensive effect and affect renal function.

Moderate Interactions (Monitor Closely): - Lithium: increased lithium levels, risk of toxicity. - Antidiabetic agents: enhanced hypoglycaemic effect. - Other antihypertensives: additive blood pressure lowering. - Corticosteroids: may counteract diuretic effect and alter electrolytes. - ACE inhibitors: combined use can increase risk of renal impairment and hyperkalaemia.